|Bid||0.5900 x 900|
|Ask||0.6100 x 1300|
|Day's range||0.5990 - 0.6300|
|52-week range||0.5600 - 1.7500|
|Beta (5Y monthly)||1.16|
|PE ratio (TTM)||N/A|
|Earnings date||14 Nov 2023 - 20 Nov 2023|
|Forward dividend & yield||N/A (N/A)|
|1y target est||5.00|
NuCana PLC Sponsored ADR (NCNA) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
EDINBURGH, United Kingdom, Sept. 18, 2023 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced four presentations at the upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023 being held October 11-15, 2023 in Boston, Massachusetts. The details of NuCana’s presentations at the meeting are as follows: Abstract title: NUC-3373 in combination with irinotecan (NUFIRI) or oxaliplatin (NUFOX) and bevacizumab for second-line treatment of patients with adva
We can readily understand why investors are attracted to unprofitable companies. For example, although...